PIR

Across TCGA pan-cancer cohorts, PIR mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PIR data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PIR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PIR expression acts as an unfavorable survival marker.

CCRCC and HNSC are the cancer types where PIR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.452	0.781	.001	81	view →
HNSC	OS	Median	All	0.626	0.808	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PIR–CCRCC (DFS)

Open the CCRCC breakdown →